CCM
GPCR icon

Camber Capital Management’s Structure Therapeutics GPCR Stock Holding History

Camber Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-300,000
Closed -$5.19M – 28
2025
Q1 		$5.19M Hold
300,000
– – 0.18% 30
2024
Q4 		$8.14M Buy
+300,000
New +$10.6M 0.19% 38

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Camber Capital Management's GPCR Position: Q2 2025 in Review

Camber Capital Management sold out of Structure Therapeutics (GPCR) in Q2 2025, closing a stake of 300,000 shares — an estimated $5.19M sold.

Camber Capital Management first reported a position in GPCR in Q4 2024 and held it in 2 quarters. The position peaked at $8.14M in Q4 2024. 172 funds tracked by Wall St. Rank hold GPCR as of Q2 2025.

  • Camber Capital Management reported no remaining Structure Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Camber Capital Management sold 300,000 Structure Therapeutics shares in Q2 2025, an estimated $5.19M.
  • Camber Capital Management first reported a position in Structure Therapeutics in Q4 2024 and held it in 2 quarters.
  • Camber Capital Management's Structure Therapeutics position peaked at $8.14M in Q4 2024.
  • 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.